脂肪性肝病的不良肝脏结局、心血管事件与死亡率
该回顾性队列研究纳入2010-2021年退伍军人健康管理局门诊影像确诊肝脂肪变的341 601例成人,按修订命名分为MASLD(77.3%)、MetALD(17.9%)和ALD(4.8%)。中位随访5.5年,与MASLD相比,MetALD不良肝脏结局发生率1.12 vs 0.61/100人年(HR 1.56,95%CI 1.50-1.62),全因死亡2.74 vs 2.60/100人年(HR 1.08,95%CI 1.05-1.10);ALD不良肝脏结局1.78 vs 0.61/100人年(HR 2.33,95%CI 2.20-2.47),全因死亡3.42 vs 2.60/100人年(HR 1.42,95%CI 1.36-1.48);MetALD和ALD的MACE发生率与MASLD相似。纤维化4指数从<1.30到>2.67,各亚型不良肝脏结局发生率约增加10倍。作者认为酒精和纤维化评估可能有助于识别长期不良结局风险增加的患者。
要点
- MetALD较MASLD不良肝脏结局发生率更高(1.12 vs 0.61/100人年,HR 1.56,95%CI 1.50-1.62),全因死亡风险略高(HR 1.08,95%CI 1.05-1.10)。
- ALD较MASLD不良肝脏结局发生率更高(1.78 vs 0.61/100人年,HR 2.33,95%CI 2.20-2.47),全因死亡风险更高(HR 1.42,95%CI 1.36-1.48)。
- MetALD和ALD的MACE发生率与MASLD相似。
- 纤维化4指数从<1.30升至>2.67,MASLD、MetALD、ALD的不良肝脏结局发生率分别从0.28升至3.02、0.39升至4.31、0.61升至5.05/100人年,约增加10倍。
- 重度饮酒、酒精使用障碍和糖尿病是与不良肝脏结局关联最强的因素。
适用人群与场景
- 2010-2021年在美国退伍军人健康管理局门诊接受诊疗、影像确诊肝脂肪变的成人。
- 共341 601例,平均(SD)年龄59.5(13.2)岁,非西班牙裔白人227 954例(66.7%),女性27 606例(8.1%)。
- 按修订命名分为MASLD 264 192例(77.3%)、MetALD 61 070例(17.9%)、ALD 16 339例(4.8%)。
诊断标准与关键阈值
- 脂肪性肝病亚型定义:MASLD为代谢功能障碍相关脂肪性肝病,ALD为酒精相关肝病,MetALD为两者交集。
- 纤维化程度用纤维化4指数评估,分层界值为<1.30与>2.67。
研究设计与关键结果
- 研究类型:回顾性队列研究;人群:影像确诊肝脂肪变的退伍军人门诊患者341 601例;暴露:MASLD、MetALD、ALD;主要终点:不良肝脏结局(肝硬化、失代偿、肝细胞癌、肝移植、肝病死亡)、MACE(心肌梗死、卒中、心力衰竭、心血管死亡)、全因死亡。
- 中位(IQR)随访5.5(3.0-8.4)年。
- MetALD vs MASLD:不良肝脏结局1.12 vs 0.61/100人年(HR 1.56,95%CI 1.50-1.62);全因死亡2.74 vs 2.60/100人年(HR 1.08,95%CI 1.05-1.10);MACE发生率相似。
- ALD vs MASLD:不良肝脏结局1.78 vs 0.61/100人年(HR 2.33,95%CI 2.20-2.47);全因死亡3.42 vs 2.60/100人年(HR 1.42,95%CI 1.36-1.48);MACE发生率相似。
- 纤维化4指数<1.30 vs >2.67的不良肝脏结局发生率(每100人年):MASLD 0.28 vs 3.02,MetALD 0.39 vs 4.31,ALD 0.61 vs 5.05,随纤维化程度升高约增加10倍。
- 与不良肝脏结局关联最强的因素为重度饮酒、酒精使用障碍和糖尿病。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,酒精和纤维化评估可能有助于识别长期不良结局风险增加的患者。
- 在影像确诊脂肪肝的患者中,区分MASLD、MetALD和ALD并评估纤维化4指数,可提供风险分层信息。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Steatotic liver disease is a major cause of advanced liver disease and is associated with increased risks of long-term adverse outcomes. However, estimates in steatotic liver disease subtypes according to the revised nomenclature are limited in population-based cohorts.
OBJECTIVE: To compare the risks of adverse liver outcomes, major adverse cardiovascular events (MACE), and all-cause mortality across steatotic liver disease subtypes.
DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study of adults with imaging-confirmed hepatic steatosis receiving outpatient care within the national Veterans Health Administration (2010-2021) was carried out. Data were analyzed from April 2024 to March 2025.
EXPOSURES: Steatotic liver disease subtypes, including metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), or their intersection (MetALD).
MAIN OUTCOMES AND MEASURES: The primary outcomes were the incidence of adverse liver outcomes (cirrhosis, decompensation, hepatocellular carcinoma, liver transplant, liver-related death), MACE (myocardial infarction, stroke, heart failure, cardiovascular death), and all-cause mortality.
RESULTS: Of 341 601 adults (mean [SD] age, 59.5 (13.2) years; 227 954 non-Hispanic White [66.7%]; 27 606 female [8.1%]), 264 192 had MASLD (77.3%), 61 070 had MetALD (17.9%), and 16 339 had ALD (4.8%). Over a median (IQR) follow-up of 5.5 (3.0-8.4) years, compared with MASLD, MetALD had a higher incidence of adverse liver outcomes (1.12 vs 0.61 per 100 person-years; hazard ratio [HR], 1.56; 95% CI, 1.50-1.62) and all-cause mortality (2.74 vs 2.60 per 100 person-years; HR, 1.08; 95% CI, 1.05-1.10), but similar incidence of MACE. ALD had a higher incidence of adverse liver outcomes (1.78 vs 0.61 per 100 person-years; HR, 2.33; 95% CI, 2.20-2.47) and all-cause mortality (3.42 vs 2.60 per 100 person-years; HR, 1.42; 95% CI, 1.36-1.48) than MASLD, but similar incidence of MACE. The incidence of adverse liver outcomes per 100 person-years increased 10-fold with a higher degree of fibrosis (Fibrosis-4 score <1.30 vs >2.67) across MASLD (0.28 vs 3.02), MetALD (0.39 vs 4.31), and ALD (0.61 vs 5.05). Severe alcohol use, alcohol use disorder, and diabetes were the factors most strongly associated with adverse liver outcomes.
CONCLUSIONS AND RELEVANCE: This cohort study found that patients with MetALD and ALD had modestly higher risks of adverse liver outcomes and all-cause mortality than those with MASLD, with similar risks of MACE. Alcohol and fibrosis assessments may help identify patients at increased risk for long-term adverse outcomes.
参考来源
- Ochoa-Allemant P, Hubbard RA, Kaplan DE, et al. Adverse Liver Outcomes, Cardiovascular Events, and Mortality in Steatotic Liver Disease. JAMA Intern Med. 2025. PMID: 40522656. doi:10.1001/jamainternmed.2025.1809
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。